Evidence map›Paper›PMID 30951840›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019

Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.

Rupa Narayan, Jonathan E Benjamin, Omid Shah, Lu Tian, Keri Tate, Randall Armstrong, Bryan J Xie, Robert Lowsky, Ginna Laport, Robert S Negrin and 1 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rupa NarayanDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Jonathan E BenjaminDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Omid ShahDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Lu TianDepartment of Health Research and Policy, Stanford University, Stanford, California.
Keri TateStanford Laboratory for Cell and Gene Medicine, Stanford, California.
Randall ArmstrongDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Bryan J XieDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Robert LowskyDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Ginna LaportDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Robert S NegrinDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Everett H MeyerDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California. Electronic address: evmeyer@stanford.edu.
Stanford University · USStanford Medicine · US

Funding

TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
TLI/ATG CONDTIONING: KIDNEY/BLOOD STEM CELL TRANSPLANTSP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2004 to 2020
$27.9M
MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
T-cell monitoring and immunotherapy for treating graft-versus-host diseaseK08HL119590 · NHLBI · STANFORD UNIVERSITY · PI MEYER, EVERETT · 2014 to 2018
$767k
NCI NIH HHS P01 CA049605NHLBI NIH HHS K08 HL119590NHLBI NIH HHS P01 HL075462
6 · The paper itself

Abstract

Non-myeloablative conditioning, such as with total lymphoid irradiation and antithymocyte globulin (TLI-ATG), has allowed allogeneic hematopoietic cell transplantation (allo-HCT) with curative potential for older patients and those with comorbid medical conditions with myeloid neoplasms. However, early achievement of full donor chimerism (FDC) and relapse remain challenging. Cytokine-induced killer (CIK) cells have been shown to have antitumor cytotoxicity. Infusion of donor-derived CIK cells has been studied for hematologic malignancies relapsed after allo-HCT but has not been evaluated as post-transplant consolidation. In this phase II study, we prospectively studied whether a one-time infusion of 1 × 10

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationMyeloproliferative DisordersTissue DonorsAdultAgedAllograftsCytokine-Induced Killer CellsDisease-Free SurvivalFemaleHumansMaleMiddle AgedSurvival RateAcute myeloid leukemiaCell therapyCytokine-induced killer cellsMyelodysplastic syndromeNon-myeloablative conditioning transplantationReduced-intensity conditioning transplantation

Identifiers

PMID30951840
PMCPMC6662740
OpenAlexW2930693567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.